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RESEARCH ARTICLE
Zoledronic acid prevents pagetic-like lesions and accelerated
bone loss in the p62P394L mouse model of Paget’s disease
Anna Daroszewska1,¶, Lorraine Rose2,*, Nadine Sarsam1,‡, Gemma Charlesworth1, Amanda Prior1,
Kenneth Rose2,§, Stuart H. Ralston2 and Robert J. van ‘t Hof1,¶
ABSTRACT
Paget’s disease of bone (PDB) is an age-related metabolic bone
disorder, characterised by focally increased and disorganised bone
remodelling initiated by abnormal and hyperactive osteoclasts. The
germline P392L mutation of SQSTM1 (encoding p62) is a strong
genetic risk factor for PDB in humans, and the equivalent mutation in
mice (P394L) causes a PDB-like disorder. However, it is unclear why
pagetic lesions become more common with age. Here, we assessed
the effect of the p62 P394Lmutation on osteoclastogenesis and bone
morphometry in relation to ageing, the natural history of lesion
progression in p62P394L mice and the effect of zoledronic acid (ZA) on
lesion development. p62P394L+/+ osteoclast precursors had increased
sensitivity to RANKL (also known as TNFSF11) compared with
wild-type (WT) cells, and the sensitivity further increased in both
genotypes with ageing. Osteoclastogenesis from 12-month-old
p62P394L+/+ mice was twofold greater than that from 3-month-old
p62P394L+/+ mice (P<0.001) and three-fold greater than that from
age-matched WT littermates. The p62P394L+/+ mice lost 33% more
trabecular bone volume in the long bones by 12 months compared with
WTmice (P<0.01), and developed pagetic-like lesions in the long bones
whichprogressedwithageing.ZAprevented thedevelopmentofpagetic-
like lesions, and increased trabecular bone volume tenfold compared
with vehicle by 12 months of age (P<0.01). This demonstrates that
ageing has a pro-osteoclastogenic effect, which is further enhanced by
the p62 P394L mutation, providing an explanation for the increased
penetranceof bone lesionswith age in thismodel. Lesionsareprevented
by ZA, providing a rationale for early intervention in humans.
KEY WORDS: Paget’s disease of bone, Genetic animal models,
Ageing, Bone morphometry, Antiresorptives, Zoledronic acid
INTRODUCTION
Paget’s disease of bone (PDB) is the second most common
metabolic bone disorder after osteoporosis and its prevalence
increases with ageing. PDB is characterised by focally increased
and disorganised bone remodelling, which leads to the formation of
poor-quality woven bone. Consequently, pain, bone expansion,
deformities, secondary osteoarthritis, pathological fractures and,
very rarely, sarcoma can develop in the skeletal sites affected by
PDB (Ralston et al., 2008).
Pagetic lesions are believed to be initiated by abnormal, enlarged,
hypernucleated and hyperactive osteoclasts, which drive the
progression of osteolysis, with increased and disorganised
osteoblast-mediated new bone formation leading to the production
of woven bone. Bisphosphonates (BPs) have been used for decades
as treatment for PDB owing to their ability to suppress osteoclast
activity, and heal lytic lesions with subsequent restoration of
histologically normal new bone deposition and symptomatic
improvement (Meunier and Vignot, 1995; Reid and Hosking,
2011; Reid et al., 1996). Currently, the most potent of the BPs,
zoledronic acid (ZA), is the treatment of choice for PDB as it
effectively suppresses bone remodelling and typically normalises
bone turnover markers, in some patients for up to 10 years (Cundy
et al., 2017). There is evidence that BPs improve pain (Corral-
Gudino et al., 2017); however, intensive treatment of established
PDB does not improve disease outcome in terms of quality of life
measures or pain (Langston et al., 2010; Tan et al., 2017), which
implies that preventive intervention, prior to lesion development,
could be a better strategy for susceptible individuals.
It has been shown that genetic predisposition to PDB is mediated
through the effects of several common predisposing variants of
moderate effect size coupled with influence of rare variants, which
have large effect size (Albagha et al., 2010, 2013). The most
important predisposing gene for PDB is sequestosome 1 (SQSTM1),
which encodes p62, a scaffolding protein involved in a variety of
cellular processes including signalling and protein degradation (Rea
et al., 2013). PDB-associated mutations of p62 tend to cluster in (but
are not limited to) the ubiquitin-associated domain and occur in up
to 40% of patients with a family history of PDB and 5-10% of
patients with ‘sporadic’ disease (Hocking et al., 2002; Laurin et al.,
2002). The most common and most studied PDB-associated p62
mutation is P392L (Hocking et al., 2002; Laurin et al., 2002).
Although it is not entirely clear how p62 mutations cause or
predispose to PDB, current evidence points to increased receptor
activator of nuclear factor kappa-B ligand (RANKL; also known as
TNFSF11)-mediated signalling enhancing osteoclastogenesis and
dysregulated protein degradation (Rea et al., 2013).
The penetrance of PDB in p62 mutation carriers rises with age to
reach between 80% and 90% by the seventh decade of life
(Morissette et al., 2006). However, recent observations of a delayed
disease onset in the p62 mutation carriers’ offspring, a less severe
disease phenotype (Bolland et al., 2007; Cundy et al., 2015) and
decreasing incidence of PDB in many countries over the past
25 years (Corral-Gudino et al., 2013; Cundy et al., 1997) suggestReceived 17 May 2018; Accepted 2 July 2018
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that nongenetic or environmental factors might play a role in
triggering the disease and/or affecting its severity. The historical
viral hypothesis is controversial owing to conflicting evidence
(Friedrichs et al., 2002; Rima et al., 2002; Visconti et al., 2017);
nevertheless, transgenic mouse models of PDB-like disorders
induced by viral sequences have been reported, suggesting that
overexpression of measles virus nucleocapsid protein in osteoclast
precursors increased osteoclast activity and bone resorption in vitro
and induced areas of high bone turnover in the vertebrae with a 30%
penetrance at 12 months of age (Kurihara et al., 2006a,b). One
group did not detect evidence of high bone turnover with the
characteristics of PDB in the vertebrae of mice bearing a knock-in
p62 P394L mutation (equivalent to the human P392L mutation)
(Hiruma et al., 2008).
We reported that although the p62 P394Lmutation seldom causes
vertebral lesions in mice, it frequently causes PDB-like lesions in
the long bones, which become increasingly penetrant with ageing
(Daroszewska et al., 2011). However, the mechanisms responsible
for the age-related increase in penetrance remain unclear and there
have been no studies on whether or not BPs could modify this
phenotype.
Here, we revisit the p62P394L model of PDB and seek to validate it
in the context of age-related osteoclastogenesis. We explore the
‘natural history’ of murine pagetic-like lesion evolution and relate it
to human pagetic lesion progression. Finally, we investigate the role
of ZA in prevention of the PDB-like phenotype.
RESULTS
Osteoclast formation increases in p62P394Lmicewith ageing
Studies in vitro showed that macrophage colony-stimulating factor
(M-CSF)- and RANKL-induced osteoclast formation from bone
marrow-derived macrophages was significantly greater in aged (12-
month-old) WT mice when compared with young adult (3-month-
old) WT mice (Fig. 1A). The number of osteoclasts generated from
young adult p62P394L+/− mice was significantly greater when
compared with young adult WT littermates, whereas the number of
osteoclasts generated from aged p62P394L+/− mice was greater when
compared with young adult and aged WT mice (Fig. 1A,B). This
effect was even more striking in the p62P394L+/+ mice. The number of
osteoclasts generated from aged p62P394L+/+ mice increased
approximately twofold when compared with young adult p62P394L+/+
mice (Fig. 1C) and threefold when compared with aged WT
littermates (Fig. 1A,C). Moreover, osteoclast precursors from
p62P394L+/+ mice showed evidence of increased sensitivity to
RANKL as compared with WT cells, at 10 ng/ml, 30 ng/ml and
100 ng/ml RANKL stimulation, which was intensified by ageing
(Fig. 1C). A similar effect was seen in osteoclast precursors
generated from the p62P394L+/−, although not as pronounced as in the
homozygotes (Fig. 1B). Thus, ageing increases RANKL-induced
osteoclastogenesis, and the p62 P394Lmutation further enhances the
age-related increase in osteoclastogenesis with a gene dosage effect.
The p62P394L mutation is associated with accelerated
age-related long bone loss
We have previously shown that there was no significant difference
in trabecular bone density and structure at the proximal tibial
metaphyses of young adult (4-month-old) p62P394L+/+ male mice
and WT littermates (Daroszewska et al., 2011). In view of the p62
P394L mutation-induced potentiation of age-related increase in
osteoclastogenesis in vitro, we asked whether the p62 P394L
mutation had an in vivo effect on age-related bone loss. We examined
the distal femoral metaphyses of 12-month-old p62P394L+/+ mice and
WT littermates using micro computed tomography (μCT). There was
a significant decrease in bone volume to total volume (BV/TV) of
33% (P<0.01), a significant decrease in trabecular number (Tb.N)
and a significant increase in trabecular separation (Tb.Sp) in aged
p62P394L+/+ mice compared with WT littermates (Fig. 2), in keeping
with accelerated age-related bone loss. There were no significant
differences in vertebral (L5) morphometry between p62P394L+/+ mice
and WT littermates (data not shown).
Evolution of pagetic-like lesions with ageing in p62P394L
mutant mice
In the PBS-treated group, 8/10 (80%) p62P394L+/+ mice developed
pagetic-like lesions in the femur and/or tibia with the morphology
described before (Daroszewska et al., 2011) by 12 months, as
compared with 0/10 (0%) in the ZA-treated p62P394L+/+ mice
(P<0.001, Fisher’s exact test; see also next section). As femoral
pagetic-lesions in patients progress linearly at an estimated rate of
9.4 mm per annum (Renier and Audran, 1997), we monitored PBS-
treated p62P394L+/+ mice in vivo with µCT to capture and follow up
lesion progression. An example of the most severe lesion observed in
this cohort and its evolution until the age of 18 months is shown in
Fig. 3. The linear progression (Fig. 3D) between the age of 8 and
10 months was from 1.173 to 2.304 mm (change of 1.131 mm);
between 10 and 15 months from 2.304 to 4.146 mm (change of
1.842 mm); and between 15 and 18 months from 4.146 to 4.696 mm
(change of 0.55 mm). Thus, the average linear progression rate was
0.37 mm per month (4.47 mm per year) to involve ∼28.5% of the
femur, given the femoral length of 16.5 mm, and the lesion gradually
expanded in 3D as well (Fig. 3). Given that mice over 6 months old
age 25× faster than humans (www.jax.org), and that a female human
femur is, on average, 445 mm long (human femur length to mouse
femur length, 445 mm/16.5 mm=26.97), the 1.131 mm change over
2 months in mouse is estimated to correspond to a 7.42 mm change
per annum in a human. Likewise, the 1.842 mm (over 5 months) and
0.55 mm (over 3 months) changes in mice correspond to 4.84 mm
and 2.41 mm growth per annum, respectively, in a human.
Fig. 1. Osteoclast formation is increased in p62P394L mice
with ageing. (A-C) Quantitation of osteoclast (OC) numbers in
M-CSF- and RANKL-stimulatedmacrophage cultures from young
adult (3-month-old) and aged (12-month-old) wild-type (WT; A),
p62P394L+/− (B) and p62P394L+/+ (C) mice. RANKL stimulation at 0,
3, 10, 30 and 100 ng/ml. Data are mean±s.d. from three
independent experiments. *P<0.05, **P<0.01, ***P<0.001
(one-way ANOVA).
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Accordingly, the average mouse lesion progression rate of 4.47 mm
per year corresponds to a 4.89 mm annual progression in human.
Effect of ZA on the development of pagetic-like lesions and
bone morphology
To clarify whether BPs could prevent the development of pagetic-
like lesions in the p62P394L+/+ mice, we chose ZA, which is a widely
used treatment for PDB and osteoporosis. We monitored for lesion
development using in vivo μCT at 1-2 month intervals, but did not
detect any pagetic-like lesions in either of the p62P394L+/+ groups
treated with ZA (hence the data were pooled). However, a
significant change in bone morphology was observed in all ZA-
treated p62P394L+/+ compared with vehicle-treated p62P394L+/+ and
untreated WT mice (Fig. 4). The cortex was significantly thickened
in the ZA-treated p62P394L+/+ mice (Fig. 4B) compared with
untreated WT mice, and more so when compared with the vehicle-
treated p62P394L+/+ mice affected by pagetic-like lesions (where
cortical thickening is part of the picture; Fig. 4C). The metaphyses
shape in the ZA-treated p62P394L+/+ micewas cylindrical as opposed
to flute-like in the vehicle-treated p62P394L+/+ and untreated WT
mice (Fig. 4D-F). The growth plate looked highly mineralised.
Trabeculae were very well preserved and plate-like as opposed to
rod-like structures seen with ageing (Fig. 4E). Although no obvious
pagetic-like lesions in the ZA-treated p62P394L+/+ mice occurred, we
observed lucencies in the significantly thickened cortex (Fig. 4E,
compare with F).
On histology examination, tartrate resistant acid phosphatase
(TRAcP)-stained osteoclasts were easily seen near the growth plate
of ZA-treated p62P394L+/+ mice (Fig. 5A,B); however, no osteoclasts
were identified within the lucencies of the thickened cortex
(Fig. 5A,C). Thus, treatment with ZA did not inhibit all
osteoclastogenesis, which was ongoing near the growth plate. The
cortical lucencies are unlikely to represent treated pagetic-like
lesions, as no disorganised bone or osteoclasts were evident
(Fig. 5A,C). Goldner’s trichrome stain showed no osteoid seams
(Fig. 5D,E), and very little calcein double label was present
(Fig. 5F,H) by 12 months in ZA-treated p62P394L+/+ mice,
suggesting suppressed new bone formation. There was very little
label in the cortical lucencies (Fig. 5F,H) [increased labelling would
be expected in active pagetic-like lesions (Daroszewska et al.,
2011)]. Bone histomorphometry analysis revealed significantly
increased bone volume per tissue volume (BV/TV) in ZA-treated
versus PBS-treated p62P394L+/+ mice (Table S1). However, bone
formation parameters – mineral apposition rate (MAR),
mineralising surface per bone surface (MS/BS) and bone
formation rate per bone surface (BFR/BS) – were significantly
reduced in the ZA- compared with PBS-treated p62P394L+/+ mice
(Table S1).
We then analysed the dynamic bone morphometry of the ZA- and
PBS-treated p62P394L+/+ mice using the obtained in vivo µCT scans.
Between 4 and 12 months of age, the PBS-treated p62P394L+/+ mice
lost endosteal, while gaining periosteal, bone at the femoral mid-
shaft, which led to an increase in bone diameter and marrow space
(Fig. 6A,C,D). In contrast, the ZA-treated mice gained both
endosteal and periosteal bone, although the periosteal bone gain
was reduced compared with that of PBS-treated control animals
(Fig. 6B-D). Treatment with ZA led to a rapid increase in trabecular
bone volume during the first 2 months (0.38±0.09 mm3/month;
Fig. 6F,G), owing to almost complete suppression of bone
resorption and a substantial increase in bone formation. Over the
next 6 months, the bone volume further increased, but at a much
slower rate (0.05±0.04 mm3/month, P<0.001; Fig. 6E-H). The
PBS-treated control p62P394L+/+ animals showed a small increase in
trabecular bone volume; however, this was partially offset by
trabecular bone loss at 6 months (net bone gain between 4 and 6
months, 0.08±0.04 mm3/month; Fig. 6E,G), and completely offset
by 12 months of age (net bone gain between 6 and 12 months,
−0.02±0.03 mm3/month; Fig. 6H).
ZA increases bone mass in p62P394L+/+ mice
In view of the striking changes in the ZA-treated p62P394L+/+ mice
bone morphology, we carried out a μCT morphometry analysis. At
12 months, BV/TV was approximately tenfold higher in the ZA-
compared with PBS-treated p62P394L+/+ mice (P<0.001; Fig. 7), in
keeping with histomorphometry findings (Table S1). Tb.Th
increased by 20% (P<0.01), Tb.Sp decreased by 60% (P<0.001)
and Tb.N increased by over sixfold (P<0.01) in the ZA-treated
group (Fig. 7). There was no significant difference between the four
mice that received six doses, and the six mice that received five
doses, of ZA; therefore, the data were pooled. Thus, ZA not only
prevented the development of pagetic-like lesions and protected
against the accelerated bone loss in the p62P394L+/+ mice, but
substantially increased bone volume and enhanced bone structure.
Long-term treatment with ZA leads to highly mineralised
bone in the p62P394L+/+ mice
Long-term administration of ZA to young adult p62P394L+/+ mice
led to suppression of bone turnover, which can result in
hypermineralisation of bone matrix (Allen and Burr, 2011).
Furthermore, during sectioning for histology, we observed that
the bone samples were brittle and caused damage to the
microtome knives, suggesting high mineralisation. To investigate
whether the bones of ZA-treated mice were indeed highly
mineralised, we performed additional scans of the distal femurs,
with increased averaging and camera binning to reduce image noise,
and analysed tissue mineralisation. The ZA-treated p62P394L+/+
mice had significantly higher bone tissue mineralisation
compared with the PBS-treated p62P394L+/+ mice (Fig. 8A). The
mean bone mineralisation density in the ZA-treated cohort was
1.47±0.031 g/cm3, compared with 1.416±0.032 g/cm3 in the PBS-
treated cohort (P<0.01). There was also an increased width of the
density distribution in the treated group (standard deviation of the
distribution 0.105±0.004 g/cm3) compared with that in the control
group (standard deviation of the distribution 0.093±0.004 g/cm3;
P<0.001) (Fig. 8B).
Fig. 2. p62P394L+/+mice showaccelerated bone loss in the long boneswith
ageing. Distal femurs of 12-month-old female p62P394L+/+ (n=7) and WT (n=6)
mice were scanned ex vivo with μCT at 4.5 μm resolution. BV/TV, bone
volume per tissue volume; Tb.Th, trabecular thickness; Tb.Sp, trabecular
separation; Tb.N, trabecular number. Data are mean±s.d. *P<0.05, **P<0.01,
***P<0.001 (Student’s t-test).
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DISCUSSION
We have previously shown that the p62 P394Lmutation is sufficient
to induce a pagetic-like phenotype in mice, characterised by focal,
asymmetric, mixed osteolytic/osteosclerotic lesions predominantly
affecting the long bones, femur and tibia, with increased penetrance
with ageing (Daroszewska et al., 2011). We also demonstrated the
presence of microtubular structures in osteoclasts within PDB-like
lesions similar to those previously reported in human PDB
(Daroszewska et al., 2011). In the present study, we examined the
effect of the p62 P394L mutation on age-related osteoclastogenesis
and bone loss, the development and progression of pagetic-like
lesions, and the prophylactic use of ZA.
It is well established that osteoclasts and osteoclast precursors
from patients with PDB, with or without the p62 P392L mutation,
are hypersensitive to RANKL (Chamoux et al., 2009; Menaa et al.,
2000; Neale et al., 2000). We have previously shown that osteoclast
precursors generated from the bone marrow of 3-month-old
p62P394L+/− and p62P394L+/+ mice were hypersensitive to RANKL,
and that both heterozygous and homozygous osteoclasts showed
higher bone resorption than the WT (Daroszewska et al., 2011).
Here, we have extended our analysis to assess the effect of ageing on
p62P394L osteoclast RANKL hypersensitivity, and found that it
increased incrementally in all groups, i.e. WT, heterozygotes and
homozygotes, with a p62 P394L allele dose effect. The in vitro
Fig. 3. Pagetic-like lesion evolution in the
p62P394L+/+ mouse. (A) A female
p62P394L+/+, PBS-treated mouse was
scanned in vivo with μCT at 18 μm
resolution, as shown, until 18 months of age
(top three rows) and an ex vivo scan was
then performed at 9 μm resolution (bottom
row). Cross-sections of 3D reconstruction
starting just above the femoral condyles and
ending at the trochanter are shown to
visualise the asymmetrical involvement of
the femoral shaft and progression over time.
The lesion details are better seen on the ex
vivo scan (bottom row, arrows). (B) To
assess the lesion in greater detail, an ex vivo
1.5 μm scan was performed (arrows point to
the lesion, which is also seen in the bottom
row of A in the second and third panel from
the left). (C) Longitudinal views of the
femoral shaft and the lesion progression and
extent (arrows). (D) The lesion was first
observed at 8 months and was coloured in
red for better identification and calculation of
the rate of progression. Note the difference in
orientation: in panels A and B versus C and
D the hip is on the right- versus left-hand
side, respectively. Owing to movement
artefacts, the 12 month scan is not shown.
m, age in months.
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findings of an age-related increase in RANKL-induced osteoclast
formation in WT concur with previous findings in mice (Cao et al.,
2005; Perkins et al., 1994) and humans (Chung et al., 2014;
Koshihara et al., 2002). The role of p62 in osteoclastogenesis has
been established by Duran and colleagues, who reported that
targeted disruption of p62 in mice impaired osteoclastogenesis
mediated by PTHrP (also known as PTHLH) (Duran et al., 2004),
whereas overexpression of the human p62 P392L mutation in
murine osteoclasts has been shown to increase osteoclastogenesis
and induce a low bone mass phenotype in young adult mice, which
progressed with ageing (Kurihara et al., 2007). Human studies have
shown that the p62 P392L variant increased osteoclast
differentiation, nuclearity and longevity (Chamoux et al., 2009).
However, our finding of age-related enhancement of already high
RANKL-induced osteoclast formation owing to the p62 P394L
mutation (with an allele dose effect) is novel, and suggests that the
p62 P394L mutation significantly potentiates osteoclastogenesis in
an otherwise already pre-osteoclast-rich ageing skeleton (Farr et al.,
2017), which intuitively might be permissive for relatively minor
stimuli to induce further ‘uncontrolled’ osteoclastogenesis and
pagetic lesions. In line with these observations, the known age-
related increase of constitutive RANKL expression in stromal cells,
osteoblasts and osteocytes (Cao et al., 2005; Chung et al., 2014;
Piemontese et al., 2017) could be a contributory factor to the
development of an osteoclast formation-permissive environment
(Hiruma et al., 2008).
As age-related bone loss coincides with increased osteoclast
activity, which is potentiated by the p62 P394L mutation, we
hypothesised that the p62 P394L mutation would cause accelerated
bone loss with ageing. We previously showed that long bone
morphometry of young adult (4-month-old) p62P394L+/+ mice was
no different toWT (Daroszewska et al., 2011). In a previous study of
the equivalent to our p62P394L+/+ transgenic mouse, Hiruma and
colleagues did not see any morphometric differences in the spine for
up to 12 months of age (Hiruma et al., 2008), and we similarly did
not find evidence of increased bone loss at the spine in the present
study (data not shown). However, we found a significant increase in
bone loss of the hind limb bones of p62P394L+/+ mice by 12 months
of age, which suggests that the p62 P394L mutation enhances age-
related bone loss, which likely becomes first apparent in the long
bones, as age-related bone loss takes place in the long bones ahead
of the vertebrae in mice (Glatt et al., 2007). Interestingly, pagetic-
like lesions also develop preferentially in the long bones
(Daroszewska et al., 2011) rather than vertebrae (Daroszewska
et al., 2011; Hiruma et al., 2008), which raises the possibility that
biomechanical factors might interact with the p62 P394L mutation
to influence where and when bone lesions develop. Locomotion
differences between human (bipedal) and mouse (quadripedal)
carry different mechanical loading, which coincides with
differences in pagetic lesion distribution: axial skeleton and the
long bones are preferentially affected in human, whereas long bones
(but not the axial skeleton) are preferentially affected in mice.
Interestingly, development of pagetic lesions in humans has been
described in bones subject to decades of supraphysiological
repetitive mechanical loading (Gasper, 1979; Solomon, 1979).
Animal work has shown that mechanical loading-induced bone
fatigue or microfractures (Cardoso et al., 2009; Noble et al., 2003;
Verborgt et al., 2000, 2002) led to apoptosis of osteocytes (key
mechanosensing cells in bone), which occurs focally. As osteocyte
apoptosis promotes focal osteoclast activation (Kogianni et al.,
2008), it is possible that in the ageing skeleton affected by the p62
P392/4L mutation, highly primed for RANKL-mediated
osteoclastogenesis, a trigger for focal pagetic lesion development
could be localised osteocyte apoptosis; for example, due to
microcracks developing with ageing, or repetitive mechanical
loading-induced bone fatigue. This hypothesis warrants further
investigation because, if confirmed, it could have significant
translational implications for carriers of the p62 P392L mutation
and affected individuals.
In terms of mechanisms underlying the increased age-related
RANKL-induced osteoclast formation potentiated by the p62
P392/4L mutation, it is possible that alterations in the autophagy
pathway play a role. Whilst DeSelm and colleagues provided
evidence for the noncanonical role of autophagy in the resorptive
function of osteoclasts (DeSelm et al., 2011), we have previously
shown increased expression of key regulatory autophagy genes –
SQSTM1, autophagy-related gene-5 (ATG5) and microtubule-
associated light chain 3 (LC3; also known as MAP1LC3A) – as
well as increased accumulation of LC3-II after treatment with
bafilomycin in pre-osteoclasts and osteoclasts, respectively,
generated from young adult p62P394L+/+ mice compared with
WT mice (Daroszewska et al., 2011), in keeping with induction of
the autophagy pathway. However, the effect of ageing on
canonical and noncanonical autophagy pathways in osteoclasts
is currently unknown.
The finding of the p62 P394 mutation’s ability to accelerate
age-related RANKL hypersensitivity of osteoclasts, paralleled by
increased bone loss in p62P394L+/+ mice, is also interesting from
the translational perspective. Although in vitro, the p62P394L+/+
osteoclasts showed the highest RANKL hypersensitivity,
heterozygous osteoclast formation was also significantly increased
Fig. 4. Effect of ZA on the p62P394L+/+ mice bone phenotype analysed by
μCT. 12-month-old female p62P394L+/+ mice were treated with ZA or PBS from
the age of 4 months. (A) μCT 3D reconstruction in transverse view of an
untreated WT mouse. (B) μCT 3D reconstruction in transverse view of the
p62P394L+/+ mouse treated with ZA; significant cortical thickening is evident.
(C) μCT 3D reconstruction in transverse view of the p62P394L+/+ mouse treated
with PBS; a pagetic-like lesion is indicated (empty arrow). (D) μCT 3D
reconstruction in longitudinal view of an untreated WT mouse. (E) μCT 3D
reconstruction in longitudinal view of the p62P394L+/+ mouse treated with ZA;
cylindrical shape, preservation of trabeculae and cortical thickening are
evident, and intracortical lucencies are indicated (arrow). (F) μCT 3D
reconstruction in longitudinal view of the p62P394L+/+ mouse treated with PBS;
the section includes the edge of the pagetic-like lesion indicated by the arrow.
Representative 3D reconstructions of femurs are shown. PBS-treated p62P394L+/+
mice, n=7; ZA-treated p62P394L+/+ mice, n=9; WT untreated mice, n=6.
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compared withWT, implying that p62P394L+/−mice could also show
accelerated bone loss with ageing. Indeed, we have previously
shown an allele dose effect of the p62 P394L mutation on the PDB-
like phenotype severity (Daroszewska et al., 2011) and, as such,
focused our investigations on homozygotes. Thus, we have not aged
heterozygotes in the current study in an effort to use the minimum
number of mice necessary in keeping with the principles of the 3Rs
(Replacement, Reduction and Refinement of Animals in Research;
https://nc3rs.org.uk). As the vast majority of patients with the p62
P392L-associated PDB are heterozygous, although rare
homozygous or compound heterozygous cases with severe
disease have been reported (Collet et al., 2007; Eekhoff et al.,
2004; Laurin et al., 2001, 2002; Morissette et al., 2006), it is unclear
whether our findings could be translated to a potentially increased
risk of osteoporosis in the carriers of the p62 P392L mutation.
Intriguingly, whilst PDB is classically considered a focal disease,
there is evidence of increased bone remodelling in sites unaffected
(Meunier et al., 1980), and possibly an increased risk of vertebral
and rib fractures, again at unaffected sites (Melton et al., 2000).
However, whether patients with PDB, p62 P392L mutation-linked
PDB or unaffected mutation carriers are at an increased risk of
osteoporosis is currently unknown.
We have previously shown that the PDB-like phenotype
penetrance in the p62P394L+/+ mice increased with ageing and
reached 70% and 95% by 8 and 12 months, respectively
(Daroszewska et al., 2011). Here, we were interested to capture
the moment of the PDB-like lesion occurrence and progression over
time. Using an in vivo μCT approach, we confirmed that the lesions
Fig. 5. Effect of ZA on the p62P394L+/+ mice bone phenotype analysed by histology. (A-C) Aniline Blue and TRAcP stain of a femur from a ZA-treated
p62P394L+/+ mouse. The top box in A delineates the part near the growth plate, where osteoclasts are clearly seen in red (B). The bottom box in A delineates part of
the cortex, where lucencies filled with bone marrow are present, but no osteoclasts are seen (C). (D) Goldner’s trichrome stain of a femur from a ZA-treated
p62P394L+/+ mouse with no visible osteoid seams. (E) Higher magnification view of the cortex delineated by the box in D. (F-H) Fluorescent microscopy of a
femur from a ZA-treated and calcein double-labelled p62P394L+/+ mouse, with Calcein Blue counterstain; very little, mostly single, calcein labelling is visible. The
top box in F delineates the part near the growth plate shown at higher magnification in G. The bottom box in F delineates part of the cortex, shown at higher
magnification in H. Arrows in G and H point to single calcein label. (I,J) Fluorescent microscopy of a femur from a PBS-treated and calcein double-labelled
p62P394L+/+ mouse, with Calcein Blue counterstain; double labelling is seen (arrows). Note that the double labelling is seen on the few trabeculae present
in the PBS-treated p62P394L+/+ mouse compared with significantly less and mostly single labelling seen in the ZA-treated p62P394L+/+ mouse, despite significantly
higher trabecular bone volume in the latter.
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had mixed osteolytic/osteosclerotic morphology and enlarged over
time, but generally did not occur before the age of 6 months. We did
not observe purely sclerotic lesions (to indicate ‘burned out’ PDB),
which can occur in long-standing PDB in some patients (Siris et al.,
1980); however, this is not unexpected given the higher rate of bone
turnover in mice, compared with humans and a relatively short
observation period, as our mice were culled at the age of 12-
18 months. We have previously shown that the lesions most
commonly developed at the distal femur and proximal tibia and less
commonly in the shaft of the long bones (Daroszewska et al., 2011),
which is comparable with a similar distribution in humans in the
long bones, albeit with more predilection for the proximal ends of
the long bones in the latter (Renier et al., 1996). Here, we presented
a lesion in the diaphysis of the femur, which progressed over time.
The estimated rate of its linear progression was equivalent to
7.42 mm per annum growth in human at early stages and later to
between 4.84 mm and 2.41 mm per annum, which compares to an
∼9.4 mm per annum linear progression of a femoral pagetic lesion
in human, according to estimations made two decades ago (Renier
and Audran, 1997), when PDB was more severe than currently.
Thus, although the murine pagetic-like lesions appear to progress at
a slower rate than the human ones, we argue that their progression is
comparable. Indeed, the slowing down of progression with ageing,
arguably could suggest eventual ‘burning out’ of the phenotype.
There is evidence that treatment with BPs inhibits PDB lesion
progression and promotes formation of histologically normal bone
(Reid et al., 1996). BPs also suppress the raised bone turnover that is
characteristic of active PDB, and ZA is the most potent BP (Corral-
Fig. 6. Effect of ZA on the bone shape of the p62P394L+/+ mice analysed by μCT. ZA- or PBS-treated p62P394L+/+ mice were scanned using a Skyscan 1076
in vivo µCT scanner (resolution 18 µm) at 4, 6 and 12 months of age. The scans were registered and femoral bone shape changes over time were analysed.
(A,B,E,F) White indicates bone lost, red indicates bone gained and blue indicates no change between the time points. A and B show changes at the mid diaphysis
between 4 and 12 months of age. PBS-treated p62P394L+/+ mice show endosteal bone loss and periosteal bone gain (A), whereas ZA-treated mice show
both endosteal and periosteal bone gain and very little bone loss (B). E and F show changes in the distal femoral metaphysis between 4 and 6 months of age. Note
the substantial increase in bone volume in the ZA-treated animal (F). (C,D) Quantification of changes in A and B. (G) Quantification of the trabecular bone volume
changes between 4 and 6 months of age. (H) Quantification of the trabecular bone volume changes between 4 and 12 months of age. Data are mean±s.d.
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-test). PBS, n=6; ZA, n=8. Anchor points added by the CTAn software have been removed from panels A, B, E and F.
Fig. 7. ZA increases bone volume in p62P394L+/+ mice.
4-month-old female p62P394L+/+ mice were treated with ZA
(n=9) or PBS (n=7) as indicated until the age of 12 months.WT
mice (n=6) were untreated. Bone morphometry of femoral
metaphyses was carried out by μCT at 4.5 μm resolution.
BV/TV, bone volume per tissue volume; Tb.Th, trabecular
thickness; Tb.Sp, trabecular separation; Tb.N, trabecular
number. Data are mean±s.d. *P<0.05, **P<0.01 (one-way
ANOVA).
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Gudino et al., 2017). Thus, we were interested to assess whether ZA
could prevent the development of pagetic-like lesions in our mouse
model. No lesions were detected in the ZA-treated p62P394L+/+ mice,
providing evidence of the efficacy of this agent in suppressing the
raised bone turnover that occurs in this mouse model of PDB.
Furthermore, the effectiveness of ZA given early, prior to lesion
development, provides pre-clinical evidence, to support the
approach used in the ZiPP study (ISRCTN11616770; https://doi.
org/10.1186/ISRCTN11616770), in which ZA is being investigated
as a means of preventing development of PDB lesions in SQSTM1
mutation carriers.
Although studying the general skeletal effect of ZA was not the
primary objective of our experiments, our study led to a number of
important observations with potential translational implications.
The positive effect of ZA on bone volume was striking, and ZA had
a profound inhibitory effect on bone resorption. Although the brittle
nature of the sections from ZA-treated mice precluded formal
measurement of bone resorption parameters by histomorphometry,
observation of the (mostly badly damaged) sections indicated a
significant reduction in osteoclast numbers in 12-month-old
ZA-treated p62P394L+/+ mice. Moreover, ZA attenuated new bone
formation, but with a net effect of increased bone volume.
Furthermore, bones of the ZA-treated p62P394L+/+ mice showed
significantly higher mineralisation compared with controls, which
suggests that ZA significantly slowed down the bone remodelling
process, which allowed for increased mineralisation over time. On
the other hand, the change of shape at the mid-femoral shaft
consequent to treatment with ZA suggests that modelling was still
taking place, although it was impaired. The dose-dependent
protective effect of ZA on bone has been described previously in
animal models of ovariectomy-induced osteoporosis (Gasser et al.,
2008). ZA is commonly used for treatment of both PDB and
osteoporosis, and long-term use of BPs has been associated with an
increased risk of atypical fractures (Schilcher et al., 2011), believed
to be facilitated by the oversuppression of bone turnover
(Compston, 2011); however, we did not observe any fractures in
any of the mice by 12 months of age. We also did not see any
evidence of microfractures on high resolution 2.5 μm scans (n=9,
data not shown). Nevertheless, we were unable to formally assess
bone strength, as the above observations were made on already fixed
bone samples analysed by µCT and histology. Regardless, the
ability of ZA to increase bone mass and promote mineralisation
(with potential consequences of accumulation of microdamage)
with impairment of remodelling and, to a degree, modelling might
have translational implications when choosing this type of treatment
for young adult individuals, especially for prolonged periods of
time, as already implied by this known effect of BPs (Allen and
Burr, 2011). Thus, given incomplete penetrance and declining
prevalence and severity of PDB, careful consideration would have
to be given when contemplating prophylactic use of ZA in
susceptible individuals, in the light of potential negative
ramifications of prolonged suppression of bone remodelling. It is
expected that the outcome of the ZiPP trial will be instrumental in
future clinical decision making.
The current study has confirmed our previous findings that the
p62 P394L mutation is sufficient to cause a PDB-like disorder in
mice and has provided new insight into the pathophysiology of the
increased age-related penetrance of this disorder. The increase in
osteoclastogenic potential of bone marrow cells from p62P394L mice
with age provides an explanation for the increased penetrance with
age that we previously observed in this model (Daroszewska et al.,
2011), and for the increased penetrance of PDB with age in humans
(Morissette et al., 2006). Furthermore, the preferential targeting of
the lower limb bones with sparing of the vertebrae suggests that
biomechanical factors could play a key role in determining where
and when lesions develop (Daroszewska et al., 2011).
In summary, we have shown that osteoclastogenesis is enhanced
with ageing and the p62 P394L mutation further increases age-
related osteoclastogenesis and age-related bone loss. In the ageing
skeleton, the p62 P394L mutation causes PDB-like lesions, which
progress over time. It is unclear what triggers these lesions;
however, the increased age-related osteoclastogenesis potentiated
Fig. 8. ZA increases bone mineralisation in p62P394L+/+
mice. 4-month-old female p62P394L+/+ mice were treated with
ZA (n=8) or vehicle (PBS, n=7) at 2 month intervals until the
age of 12 months. Bone mineralisation was assessed at the
same level in the diaphysis of the femoral bones. (A) The ZA-
treated mice have highly mineralised bones compared with the
vehicle-treated controls. (B) The bone tissue mineral density
(TMD) is significantly higher in the ZA-treated mice compared
with controls. The graph shows the density distribution within
the bone tissue. The samples from ZA-treated mice show
significantly higher mean density, and awidening of the density
distribution.
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by the p62 P394L mutation seems to allow for lesion development,
thus creating a permissive environment. ZA prevents the
development of the PDB-like lesions, significantly increases bone
volume and bone mineralisation, and interferes with age-related
long bone shape changes.
MATERIALS AND METHODS
p62P394L+/+ mice
The p62P394L+/+ mice were generated by gene targeting as previously
described (Daroszewska et al., 2011) and housed in a standard animal facility
with free access to water and food. The study was conducted in accordance
with institutional, national and European regulations of laboratory animal care
and use, and approved by the Home Office (UK). The mice were on a mixed
129/sv and C57/BL6 background, and the colonies were maintained by
breeding heterozygotes; WT, heterozygous and homozygous animals used in
this study were littermates. As in this mouse model of PDB, there is no
phenotypic difference betweenmales and females (Daroszewska et al., 2011),
for the assessment of ZA (Novartis) in prevention of pagetic-like lesion
development, ten female p62P394L+/+ micewere randomly allocated to receive
treatment with ZA in phosphate-buffered saline (PBS) at a dose of 85 µg/kg
subcutaneously (equivalent to a human 5 mg/60 kg dose) as of 4 months of
age, at which age mice are fully mature, but have no detectable pagetic-like
lesions (Daroszewska et al., 2011). Of the ZA-treated p62P394L+/+ mice, four
mice received three doses of ZA at monthly intervals and three subsequent
doses at 2 month intervals (six doses in total). The remaining six mice
received a total of five doses at 2 month intervals. The initial frequency of ZA
administration at monthly intervals is approximately equivalent to 5 mg given
at 2 year intervals to a human three times [given that a mouse ages 25× faster
than a human (www.jax.org)]. Likewise, the frequency of administration of
ZA 2 months apart to mice corresponds to 5 mg given 4.2 years apart to a
human. This frequency corresponds broadly to the approach used in clinical
practice for treatment of osteoporosis (three to six times annually) and PDB
(repeat treatment depending on response). Ten control female p62P394L+/+
mice were randomly allocated to receive PBS alone at the same time points.
These numbers were arrived at assuming that ZAwould reduce the proportion
of mice with lesions from 95% [as previously reported (Daroszewska et al.,
2011)] to 19% by 12 months with a power of 80% and an α<0.05. ZA-treated
mice were culled at 12 months. Most of the control PBS-treated p62P394L+/+
mice were culled at 12 months using cervical dislocation, but a small cohort
was maintained until a maximum of 18 months. One of the control mice died
after anaesthesia at 8 months and was replaced by an additional mouse.
Cell culture
Bone marrow was obtained from 3- and 12-month-old mice. Osteoclasts
were generated by treatment of macrophages withM-CSF (Prospec Bio) and
RANKL (kindly donated by Dr Jim Dunford, University of Oxford, Oxford,
UK), according to standard methods as previously described (Idris et al.,
2008). RANKL dose response was performed in 96-well plates. Numbers of
osteoclasts were counted after TRAcP staining by an observer blinded to
genotype and mouse age.
μCT analysis
The skin was removed and hind limbs were fixed in 4% formalin-buffered
saline and stored in 70% ethanol. μCT analysis was performed using a
Skyscan 1272 or the in vivo Skyscan 1076 system. For assessment of bone
morphometry, femurs and the lumbar spine were dissected free of most soft
tissue, and scanned at a resolution of 4.5 µm (60 kV, 150 µA, using a
0.5 mm aluminium filter). Samples with pagetic-like lesions in the distal
femur were excluded from the morphometry analysis. The reconstruction
was performed using the Skyscan NRecon package. Trabecular bone
parameters were measured using Skyscan CTAn software in a stack of 200
slices immediately proximal to the growth plate as described (van ‘t Hof,
2012). To screen for the presence of lesions and follow up lesion
progression, mice were scanned in vivo at 18 µm resolution at 1-2 month
intervals between the age of 4 and 12 months (and at age 15 and 18 months
where indicated) under general anaesthesia using halothane. Assessment of
lesions was performed by an observer blinded to genotype and treatment
allocation after reconstruction as described (Daroszewska et al., 2011).
Skyscan dataviewer software was used to register the series of in vivo scans
for assessment of lesion evolution and bone changes over time. Bone
changes over time were analysed in 100 slices at the mid shaft of the femur
for cortical bone analysis, and in 100 slices at the distal femoral metaphysis,
for trabecular bone changes using macros in CTAn. In the cortex, any bone
changes in contact with the marrow space in the 4 month scans were
designated as endosteal, whereas changes in contact with the periosteal
outline of the 4 month scans were designated as periosteal. For analysing
trabecular changes, the macro used first separated the trabecular from the
cortical compartment in 4 month scans, and subsequently measured
the bone gain and loss in the trabecular compartment by subtracting the
registered scans for the 6 and 12 month time points.
Finally, to analyse tissue mineralisation, samples were equilibrated
overnight in water, and the distal femur scanned inside drinking straws using
a Skyscan1272 scanner (resolution 4.5 µm, X-ray source at 50 kV and
200 µA, 0.5 mm Al filter, camera binning 2×2, rotation step size 0.3°,
averaging at 3). Hydroxy-apatite standards (Skyscan), were scanned using
identical settings to calibrate mineral density. Next, datasets consisting of
300 slices at the mid shaft of the femur were thresholded to identify bone,
and the binary was eroded (3D space) with a sphere with a radius of 2 to
remove voxels affected by partial voxel effects. This binary was then used as
a mask to measure the mineral density in mineralised tissue only [the tissue
mineral density (TMD)].
Bone histology
Bone samples were processed and stained for histology as described by van ‘t
Hof et al. (2017). Briefly, animals received calcein intraperitoneal injections
4 days and 1 day before culling. The skin was removed, hind limbs were fixed
for 24 h in 4% formalin and stored in 70% ethanol. The samples were
embedded in methyl methacrylate and 5 µm sections were cut using a tungsten
steel knife. Sections were stained for TRAcP to visualise osteoclasts and
counterstained with Aniline Blue. For analysis of calcein double labelling,
sections were counterstained with Calcein Blue and histomorphometry
performed as described by van ‘t Hof et al. (2017). All sections were
visualised on a Zeiss Axioimager fluorescence microscope fitted with a
QImaging Retiga 4000R digital camera. The histology assessment was
performed by an observer blinded to genotype and treatment allocation.
Statistical analysis
Statistical analyses were performed using SPSS version 21. Differences
between genotype or treatment groups were determined by ANOVA,
Student’s t-test or Fisher’s exact test. All data are presented as means±s.d.
unless stated otherwise.
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